TScan Therapeutics, Inc.
TCRX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.20
KIRA · Stoqly’s AI analyst, in plain words
- TScan Therapeutics, Inc. had $10.3M of revenue in fiscal 2025, up 266.7% on the year before. Over five years, revenue changed +56.9% a year on average.
- Its operating margin was −1,315.4%, up 3,472.3 pts: of every 100 in sales, about −1,315 is left after running the business.
- TScan Therapeutics, Inc. lost $130M in fiscal 2025.
- Free cash flow was −$140M in fiscal 2025, −1,353.3% of revenue.
- TScan Therapeutics, Inc. has $120M more cash than debt.
Market cap
$26.4M
P/E
—
Revenue
$10.3M
Net income
−$130M
Free cash flow
−$140M
Operating margin
−1,315.4%
TScan Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+266.7%
Yes. Sales grew 266.7% last year.
Does it make a profit?
−1,256.8%
No. It lost money last year.
Does profit turn into cash?
−1,353.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What TScan Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- TScan Therapeutics, Inc.
- CIK
- 0001783328
TScan Therapeutics, Inc. · TCRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $10.1M | $13.5M | $21.0M | $2.8M | $10.3M |
| Revenue growth | 834.7% | 33.5% | 55.5% | −86.6% | 266.7% |
| Operating margin | −479.6% | −492.3% | −444.0% | −4,787.7% | −1,315.4% |
| Net income | −$48.6M | −$66.2M | −$89.2M | −$127M | −$130M |
| Net margin | −479.5% | −489.3% | −423.9% | −4,527.7% | −1,256.8% |
| Diluted EPS | −$4.17 | −$2.75 | −$1.36 | −$1.14 | −$1.00 |
| Cash | |||||
| Cash from operations | −$48.7M | −$66.5M | −$61.4M | −$111M | −$135M |
| Capital expenditure | $9.9M | $4.2M | $3.1M | $3.8M | $4.4M |
| Free cash flow | −$58.6M | −$70.7M | −$64.5M | −$115M | −$140M |
| FCF margin | −578.0% | −522.6% | −306.4% | −4,071.3% | −1,353.3% |
| Share count change | 1,173.2% | 106.2% | 172.8% | 70.7% | 15.9% |
| Debt and strength | |||||
| Cash and short-term investments | $161M | $120M | $192M | $290M | $152M |
| Debt incl. finance leases | — | $29.3M | $30.0M | $32.1M | $32.5M |
| Shareholders' equity | $161M | $99.4M | $151M | $241M | $123M |
| Current ratio | 7.8x | 7.2x | 6.5x | 8.1x | 8.4x |
| Interest coverage | — | −56.7x | −24.9x | −36.9x | −49.0x |
| Returns and quality | |||||
| Return on capital | — | −605.3% | — | — | −3,300.3% |
| Return on equity | −82.2% | −50.9% | −71.3% | −65.1% | −71.3% |
| Return on tangible equity | −30.2% | −66.6% | −59.1% | −52.9% | −105.4% |
| Piotroski F-score | 3 | 1 | 4 | 3 | 2 |
| Altman Z'' | 7.9 | −0.3 | −0.0 | 0.7 | −6.0 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
TScan Therapeutics, Inc. · TCRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.20 a share, the company is worth $26.4M.
Source: SEC EDGAR XBRL filings (CIK 0001783328). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.